Active substance
Nifedipine
- SFDA 8
- US FDA 38
- Health Canada 12
- US price lines 8
- NHS prices 10
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ADALAT 30MG LA TAB | 30 mg | modified-release tablet · Oral use | 30 Blister | SAR 46.40 | NCE · Prescription | BAYER PHARMA AG | Valid |
| EPILAT 10MG CAPS | 10 mg | Capsule, soft · Oral use | 30 Blister | SAR 6.45 | Generic · Prescription | EIPICO | Valid |
| ADALAT 60MG LA TAB | 60 mg | modified-release tablet · Oral use | 30 Blister | SAR 58.50 | NCE · Prescription | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| ADALAT CAP 10MG | 10 mg | Capsule · Oral use | 30 Blister | SAR 28.70 | NCE · Prescription | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| ADALAT RETARD 20MG TABS | 20 mg | modified-release tablet · Oral use | 30 Blister | SAR 37.65 | NCE · Prescription | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| NIFECARD 10 CAPS | 10 mg | Capsule · Oral use | 30 Blister | SAR 16.30 | Generic · Prescription | DAR ALDAWA | Withdrawn by MAH · Not Marketed |
| NOVO-NIFEDIN 10MG CAPS. | 10 mg | Capsule, soft · Oral use | 30 Blister | SAR 24.65 | Generic · Prescription | NOVOPHARM | Withdrawn by MAH · Not Marketed |
| NOVO-NIFEDIN 10MG CAPS. | 10 mg | Capsule, soft · Oral use | 100 Blister | SAR 78.35 | Generic · Prescription | NOVOPHARM | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANAL FISSURE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; HYPERTENSION; MATERNAL AND CHILD HEALTHCARE- PREVENTION OF PRETERM LABOR AND BIRTH; NEONATAL RESPIRATORY DISTRESS SYNDROME (NRDS); PRE-ECLAMPSIA; PULMONARY ARTERIAL HYPERTENSION; RAYNAUD'S PHENOMENON; RENAL AND URETERIC STONES; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OF ALTITUDE SICKNESS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NIFEDIPINE | 10MG | capsule · oral | ACTAVIS ELIZABETH | Prescription | 28 Apr 1989 |
| PROCARDIA XL | 30MG; 60MG | tablet, extended release · oral | PFIZER | Prescription | 6 Sep 1989 |
| NIFEDIPINE | 10MG | capsule · oral | VELZEN PHARMA PVT | Prescription | 8 Oct 1991 |
| NIFEDIPINE | 20MG | capsule · oral | VELZEN PHARMA PVT | Prescription | 30 Apr 1992 |
| NIFEDIPINE | 10MG | capsule · oral | ACELLA | Prescription | 30 Jul 1993 |
| NIFEDIPINE | 60MG; 30MG | tablet, extended release · oral | VALEANT PHARMS NORTH | Prescription | 27 Sep 2000 |
| NIFEDIPINE | 30MG; 60MG | tablet, extended release · oral | VALEANT PHARMS NORTH | Prescription | 4 Dec 2000 |
| NIFEDIPINE | 90MG | tablet, extended release · oral | VALEANT PHARMS NORTH | Prescription | 16 Aug 2002 |
| NIFEDIPINE | 90MG | tablet, extended release · oral | MARTEC USA LLC | Prescription | 23 Mar 2004 |
| NIFEDIPINE | 30MG; 60MG; 90MG | tablet, extended release · oral | OSMOTICA PHARM US | Prescription | 21 Nov 2005 |
| NIFEDIPINE | 10MG; 20MG | capsule · oral | HERITAGE PHARMA | Prescription | 25 Apr 2013 |
| NIFEDIPINE | 30MG; 60MG; 90MG | tablet, extended release · oral | TWI PHARMS | Prescription | 3 Apr 2014 |
| NIFEDIPINE | 30MG; 60MG; 90MG | tablet, extended release · oral | NOVAST LABS | Prescription | 25 Aug 2016 |
| NIFEDIPINE | 30MG; 60MG; 90MG | tablet, extended release · oral | ZYDUS PHARMS | Prescription | 19 Dec 2017 |
| NIFEDIPINE | 30MG; 60MG; 90MG | tablet, extended release · oral | ZYDUS PHARMS | Prescription | 29 Jun 2018 |
| NIFEDIPINE | 30MG; 60MG; 90MG | tablet, extended release · oral | NOVAST LABS | Prescription | 12 Mar 2019 |
| NIFEDIPINE | 90MG | tablet, extended release · oral | ELITE PHARM SOLUTION | Prescription | 18 Nov 2020 |
| NIFEDIPINE | 30MG; 60MG; 90MG | tablet, extended release · oral | AUROBINDO PHARMA | Prescription | 19 Jul 2021 |
| NIFEDIPINE | 30MG; 60MG; 90MG | tablet, extended release · oral | ALKEM LABS LTD | Prescription | 29 Mar 2022 |
| NIFEDIPINE | 30MG; 60MG; 90MG | tablet, extended release · oral | ALEMBIC | Prescription | 18 Nov 2022 |
| PROCARDIA | 10MG; 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | PFIZER | Discontinued | 31 Dec 1981 |
| ADALAT | 10MG; 20MG | capsule · oral | BAYER PHARMS | Discontinued | 27 Nov 1985 |
| NIFEDIPINE | 20MG | capsule · oral | ACTAVIS ELIZABETH | Discontinued | 28 Apr 1989 |
| NIFEDIPINE | 10MG | capsule · oral | CHASE LABS NJ | Discontinued | 10 Jul 1989 |
| PROCARDIA XL | 90MG | tablet, extended release · oral | PFIZER | Discontinued | 6 Sep 1989 |
13 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ADALAT XL | 02155907 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | BAYER INC |
| AG-NIFEDIPINE ER | 02511460 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | ANGITA PHARMA INC. |
| JAMP NIFEDIPINE ER | 02511711 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | JAMP PHARMA CORPORATION |
| M-NIFEDIPINE ER | 02511649 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | MANTRA PHARMA INC |
| MYLAN-NIFEDIPINE EXTENDED RELEASE | 02321149 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
| MYLAN-NIFEDIPINE EXTENDED RELEASE | 02349167 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
| NIFEDIPINE | 00725110 | 5 MG | CAPSULE · ORAL | AA PHARMA INC |
| NIFEDIPINE | 00755907 | 10 MG | CAPSULE · ORAL | AA PHARMA INC |
| NIFEDIPINE ER | 02421658 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | PRO DOC LIMITEE |
| PMS-NIFEDIPINE ER | 02416301 | 60 MG | TABLET (EXTENDED-RELEASE) · ORAL | PHARMASCIENCE INC |
| PMSC-NIFEDIPINE ER | 02533332 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | PHARMASCIENCE INC |
| PRO-NIFEDIPINE ER | 02534843 | 30 MG | TABLET (EXTENDED-RELEASE) · ORAL | PRO DOC LIMITEE |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | NIFEDIPINE 10 MG CAPSULE | $0.25672 | per EA | 23 Sep 2026 |
| US NADAC | NIFEDIPINE 20 MG CAPSULE | $0.68559 | per EA | 23 Sep 2026 |
| US NADAC | NIFEDIPINE ER 30 MG TABLET | $0.13006 | per EA | 23 Sep 2026 |
| US NADAC | NIFEDIPINE ER 30 MG TABLET | $0.11663 | per EA | 23 Sep 2026 |
| US NADAC | NIFEDIPINE ER 60 MG TABLET | $0.16809 | per EA | 23 Sep 2026 |
| US NADAC | NIFEDIPINE ER 60 MG TABLET | $0.16266 | per EA | 23 Sep 2026 |
| US NADAC | NIFEDIPINE ER 90 MG TABLET | $0.26915 | per EA | 23 Sep 2026 |
| US NADAC | NIFEDIPINE ER 90 MG TABLET | $0.25884 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Nifedipine 10mg capsules | £77.94 | 90 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Nifedipine 10mg modified-release capsules | £3.90 | 60 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Nifedipine 10mg modified-release tablets | £9.23 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Nifedipine 20mg modified-release capsules | £5.41 | 60 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Nifedipine 20mg modified-release tablets | £10.06 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Nifedipine 30mg modified-release capsules | £4.89 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Nifedipine 30mg modified-release tablets | £9.70 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Nifedipine 5mg capsules | £63.60 | 90 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Nifedipine 60mg modified-release capsules | £7.34 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Nifedipine 60mg modified-release tablets | £11.20 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 22.5. Antioxytocics (tocolytics) · core
Preterm labour without delivery
Oral > Solid: 10 mg (immediate-release)
Combinations containing Nifedipine
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.